Tricyclic 2′-C-Modified Nucleosides as Potential Anti-HCV Therapeutics
Links to Files
Author/Creator ORCID
Date
Type of Work
Department
Program
Citation of Original Publication
Wauchope, Orrette R., Matthew J. Tomney, Joseph L. Pepper, Brent E. Korba, and Katherine L. Seley-Radtke. “Tricyclic 2′-C-Modified Nucleosides as Potential Anti-HCV Therapeutics.” Organic Letters 12, no. 20 (October 15, 2010): 4466–69. https://doi.org/10.1021/ol101482h.
Rights
This document is the Accepted Manuscript version of a Published Work that appeared in final form in Organic Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/ol101482h.
Abstract
Promising biological activity in a number of therapeutic areas has been reported for both tricyclic nucleosides and 2′-modified nucleosides. In particular, disubstitution at the C-2′ position of nucleosides has resulted in significant activity against the hepatitis C virus (HCV). Combining this with the observation that tricyclic nucleosides developed in our laboratory have been shown to inhibit the RNA-dependent RNA polymerase NS5B led to the design of a series of 2′-modified tricyclic nucleosides. Details of the synthesis, structural characterization, and preliminary biological results are reported.